Zinc-alpha2-glycoprotein, dysglycaemia and insulin resistance: a systematic review and meta-analysis
- PDF / 263,832 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 96 Downloads / 189 Views
Zinc-alpha2-glycoprotein, dysglycaemia and insulin resistance: a systematic review and meta-analysis Harriet M. Pearsey 1,2,3 & Joseph Henson 1,2 & Jack A. Sargeant 1,2 & Melanie J. Davies 1,2 & Kamlesh Khunti 1,4 & Toru Suzuki 2,5 & Kelly A. Bowden-Davies 6 & Daniel J. Cuthbertson 7,8 & Thomas E. Yates 1,2
# The Author(s) 2020
Abstract To systematically review the current literature investigating associations between zinc-alpha2-glycoprotein (ZAG) and dysglycaemia (including type 2 diabetes (T2DM), poly-cystic-ovary syndrome (PCOS), pre-diabetes or insulin resistance). This included relationships between ZAG and continuous measures of insulin and glucose. Additionally, we performed a meta-analysis to estimate the extent that ZAG differs between individuals with or without dysglycaemia; whilst examining the potential influence of adiposity. A systematic search was performed on four databases for studies on circulating ZAG concentrations in adult human populations, comparing healthy controls to individuals with dysglycaemia. Key characteristics, including the mean ZAG concentrations (mg∙L−1), and any correlational statistics between ZAG and continuous measures of glucose, glycated haemoglobin (HbA1c) or insulin were extracted. Meta-analyses were performed to compare metabolically healthy controls to cases, and on studies that compared controls and cases considered overweight or obese (body mass index (BMI) ≥25 kg.m2). 1575 papers were identified and 14 studies (16 cohorts) were considered eligible for inclusion. Circulating ZAG was lower in individuals with dysglycaemia compared to metabolically healthy controls (−4.14 [−8.17, −0.11] mg.L−1; I2 = 98.5%; p < 0.001). When using data from only studies with overweight or obese groups with or without dysglycaemia (three studies (four cohorts); pooled n = 332), the difference in circulating ZAG was no longer significant (−0.30 [−3.67, 3.07] mg. L−1; I2 = 28.0%; p = 0.225). These data suggest that ZAG may be implicated in dysglycaemia, although there was significant heterogeneity across different studies and the mediating effect of adiposity cannot be excluded. Therefore, more research is needed before robust conclusions can be drawn. Keywords Alpha-2-glycoprotein, zinc . AZGP1 . Hyperglycaemia . Dysglycaemia . Insulin resistance Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11154-020-09553-w) contains supplementary material, which is available to authorized users. * Harriet M. Pearsey [email protected] 1
Diabetes Research Centre, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK
2
NIHR Leicester Biomedical Research Centre, Leicester, UK
3
Department of Health Science, University of Leicester, Leicester, UK
4
NIHR ARC East Midlands, Leicester, UK
5
Cardiovascular Sciences Unit, Leicester Glenfeild Hospital, Leicester, UK
6
School of Biomedical Sciences, Newcastle University, Newcastle, UK
7
Clinical Sciences Centre, Aintree University Hospitals NHS Foundation Trust, Liverpool, UK
8
Facult
Data Loading...
